Hemogenyx Pharmaceuticals outlines significant progress with HEMO-CAR-T in 2023

Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF) CEO Dr Vladislav Sandler tells Proactive's Stephen Gunnion that 2023 was a significant year for the...

Related Keywords

Stephen Gunnion ,Vladislav Sandler ,Drug Administration ,Hemogenyx Pharmaceuticals ,Investigational New Drug ,Prevail Infoworks ,Chimeric Bait Receptor ,